 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LB1901 / Legend Biotech
LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL) (Section 34) - Mar 9, 2022 - Abstract #AACR2022AACR_4618;
P1
Secondary endpoints include overall response rate; duration of response; CAR-positive T cell counts and CAR transgene level in blood; and presence of anti-CAR antibody response. Exploratory endpoints include preliminary efficacy, pharmacokinetics, and CD4+ T cell counts.
- || LB1901 / Legend Biotech
Enrollment closed, CAR T-Cell Therapy: LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov) - Feb 16, 2022
P1, N=50, Active, not recruiting, Sponsor: Legend Biotech USA Inc
Exploratory endpoints include preliminary efficacy, pharmacokinetics, and CD4+ T cell counts. Recruiting --> Active, not recruiting
- || LB1901 / Legend Biotech
Enrollment open, CAR T-Cell Therapy: LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov) - Sep 17, 2021
P1, N=50, Recruiting, Sponsor: Legend Biotech USA Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | LB1901 / Legend Biotech
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov) - Jun 8, 2021
P1, N=50, Not yet recruiting, Sponsor: Legend Biotech USA Inc
Not yet recruiting --> Recruiting Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2023
- LB1901 / Legend Biotech
[VIRTUAL] Preclinical analysis of an autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3917;
P1
the CD4 antigen but exhibited potent anti-tumor activity without off-target effects . A phase 1 study of LB1901 CAR-T in patients with relapsed or refractory PTCL or CTCL is ongoing in the US to assess the safety and tolerability of LB1901 CAR-T (NCT04712864).
- | LB1901 / Legend Biotech
New P1 trial, CAR T-Cell Therapy: LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov) - Jan 14, 2021
P1, N=50, Not yet recruiting, Sponsor: Legend Biotech USA Inc